
SINT Stock Forecast & Price Target
SINT Analyst Ratings
Bulls say
SINTX Technologies Inc. has demonstrated a significant growth trajectory by expanding its focus from silicon nitride medical devices to a broader array of biomedical, technical, and antipathogenic applications, providing strong potential for revenue diversification. The company is witnessing a ramp-up in biomedical commercialization, alongside a recent acquisition that is expected to enhance its market position and drive future performance. Additionally, the anticipated growth in the global antimicrobial fertilizer and crop protection market, projected to reach up to $10 billion by 2030, presents a substantial opportunity for SINTX, further contributing to a positive outlook for its stock value.
Bears say
SINTX Technologies reported a significant net loss of $10.3 million, resulting in an earnings per share (EPS) of $(3.46), which starkly contrasted with estimates of $(0.55). This substantial overshoot in loss highlights ongoing financial challenges within the company, particularly when considering a previous net loss of $2.3 million with an EPS of $(0.91) that fell short of estimates as well. Additionally, various risks, including balance sheet and liquidity concerns, regulatory hurdles, and the competitive landscape, further compound the uncertainty surrounding the company's future financial performance.
This aggregate rating is based on analysts' research of SINTX Technologies Inc and is not a guaranteed prediction by Public.com or investment advice.
SINT Analyst Forecast & Price Prediction
Start investing in SINT
Order type
Buy in
Order amount
Est. shares
0 shares